BRIEF—Evaluation of the Impact of German SHI Financial Stabilization Act

30 October 2023

A posting on the website of the German pharma trade group, the VFA, reveals a new report on evaluating the impact of the country’s SHI Financial Stabilization Act on patient access to medicines and on German business location.

This calls for action on:

Strengthening negotiations in the AMNOG process (which was established to find the best solutions for new medicines in the healthcare system) by abolishing the anti-innovation "guard rails" of the GKV-FinStG and the combination discount.
Refine and evolve AMNOG for novel therapeutic approaches and the new European health technology assessment process.
Ensure reliable framework conditions to support Germany and Europe as hubs of innovative research and production.
Ensure reliable framework conditions to support Germany and Europe as hubs of innovative research and production

Download